恒瑞医药(600276.SH)子公司HRS-7535片获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HRS-7535 tablets, which will be conducted soon. The indication for this product is intended for the treatment of hypertension combined with overweight or obesity [1] Group 1 - HRS-7535 tablets are a novel oral small molecule GLP-1 receptor agonist that promotes insulin secretion from the pancreas and reduces glucagon secretion while inhibiting gastric emptying through the activation of human GLP-1R [1] - The drug also enhances satiety and suppresses appetite through central mechanisms, directly reducing energy intake, making it suitable for the treatment of type 2 diabetes (T2DM) and weight loss [1] - There are currently no oral small molecule GLP-1 receptor agonists available in the global market [1] Group 2 - The cumulative research and development investment for HRS-7535 tablets has reached approximately 369.4 million yuan [1]